Analysts have reiterated their price target for USANA Health Sciences at $39.00, citing consistent assumptions in revenue growth, profit margin, and valuation multiples. These factors support a stable outlook.
What's in the News
- USANA Health Sciences was dropped from multiple S&P indexes, including the S&P 600, S&P Composite 1500, S&P 1000, and S&P 600 Consumer Staples sector (Key Developments).
- The company is actively seeking M&A opportunities to diversify its business. This was outlined during its third quarter earnings call by CEO Jim Brown (Key Developments).
- USANA revised its fiscal year 2025 guidance downwards, projecting lower net sales and earnings compared to prior expectations (Key Developments).
- USANA's maximum-strength Vitamin D supplement received the ConsumerLab.com Seal of Approval for purity, potency, and label accuracy (Key Developments).
- Updates to the Celavive skincare brand and the Nutritionals product line include enhanced formulations and new offerings targeting skin health, muscle retention, cardiovascular function, and daily wellness (Key Developments).
Valuation Changes
- Consensus Analyst Price Target remains unchanged at $39.00, reflecting continued confidence in fair value assumptions.
- Discount Rate has decreased slightly from 7.44% to 7.43%, indicating a minor adjustment in perceived risk.
- Revenue Growth expectations are steady at 21.34%, showing no change in projected top-line expansion.
- Net Profit Margin holds at 6.08%, suggesting a stable profitability outlook.
- Future P/E ratio has decreased marginally from 13.85x to 13.85x, signaling an almost unchanged valuation multiple.
Have other thoughts on USANA Health Sciences?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.